Top-Line Data of Phase II/III HEALEY ALS Platform Trial Shows Improvements in Function and Mortality
Despite improvements, results from the study of SLS-005 (IV trehalose), a low molecular weight disaccharide, did not meet statistical significance.
Top-line data from the Phase II/III HEALEY amyotrophic lateral sclerosis (ALS) clinical trial showed a 13% improvement in function and mortality with an 88% success probability (versus the pre-specified 98%), according to a press release.1 Performed in collaboration with The Sean M. Healey and AMG Center, the study is evaluating Seelos Therapeutics’ SLS-005 (IV trehalose), a low molecular weight disaccharide. It functions by stabilizing misfolded proteins and activating autophagy.
Seelos received top-line results for regimen E, which includes a full analysis set, efficacy regimen only population and an efficacy RELYVRIO free population. The full analysis set includes shared placebo from all regimens.
In addition to the improvements in function and mortality, data showed a potential signal of efficacy in a pre-specified subgroup. However, the study did not meet statistical significance in the primary and secondary endpoint in the full analysis set.
According to an estimate from the Centers for Disease Control and Prevention, there are over 31,000 patients living with ALS in the United States as of 2017. On average 5,000 new patients are diagnosed with ALS every year.2
"The HEALEY platform is designed to detect signals of efficacy and we believe the observed signal and success probability is competitive to other recently FDA-approved therapies for ALS which also failed to achieve statistical significance when measured for function and mortality on similar primary and efficacy endpoints," Raj Mehra PhD, chairman and chief executive officer of Seelos said in the press release. "We plan to request a meeting with the FDA to discuss potential next steps for the program and will continue our potential partner discussions."
SLS-005 has previously received Orphan Drug Designation for the treatment of ALS from FDA and EMA. In addition to the Phase II/III HEALEY ALS Platform Trial, Seelos announced results from an in vivo study of SLS-005 in an aggressive Alzheimer's disease non-human primate model in September 2023.3
References
1. Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose). News release. March 19, 2024. Accessed March 20, 2024. https://www.prnewswire.com/news-releases/seelos-therapeutics-provides-update-on-top-line-results-from-its-amyotrophic-lateral-sclerosis-als-study-with-sls-005-iv-trehalose-302092918.html
2. Amyotrophic lateral sclerosis. Centers for Disease Control and Prevention, U.S. Department of Health & Human Services. Accessed March 20, 2024. https://www.cdc.gov/als/WhatisALS.html
3. Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease. News release. September 27, 2023. Accessed March 20, 2024. https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-encouraging-data-from-an-in-vivo-study-of-sls-005-in-an-aggressive-preclinical-model-of-alzheimers-disease-301939596.html
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
